期刊文献+

参附注射液对晚期结直肠癌化疗患者白细胞的影响 被引量:3

下载PDF
导出
摘要 目的探讨晚期结直肠癌患者化疗过程中使用参附注射液对患者白细胞的影响情况。方法整理36例晚期结直肠癌患者的临床资料,在化疗治疗过程中按照自愿原则分为治疗组和对照组,治疗组化疗治疗过程中加入参附注射液进行联合治疗,对照组患者联合使用0.9%氯化钠注射液进行治疗,完成治疗之后对患者的白细胞进行检测,观察患者的白细胞数量变化,比较两种不同药物治疗下患者的白细胞影响情况。结果治疗组患者完成治疗之后,患者的白细胞数量正常比例较多,与对照组相比差异有统计学意义P<0.05。结论在临床化疗治疗晚期结直肠癌患者的过程中,可以使用参附注射液进行治疗,提高患者的临床治疗效果,稳定患者的白细胞情况,在临床上可以进行推广使用。
作者 王锦鹏
出处 《中国实用医药》 2012年第21期166-167,共2页 China Practical Medicine
  • 相关文献

参考文献4

  • 1Van Cutsem E,Cunningham D,Ten Bokkel Huinink WW,et al.Clinical activity and benefit of irinotecan(CPT-11)inpatients with colorectal cancer truly resistant to 5-fluorouracil(5-FU).Eur J Cancer,2009,35(1):55-59.
  • 2Van Iamr JAM,Rustum YM,Ackland SP,et al.Comparison of5-fluoro-2'-deoxyuridine with 5-fluorouracil and theirrole in the treat-ment of colorectal cancer.Eur J Cancer,2008,34(3):296-306.
  • 3Douillard JY,Cunningham D,Roth AD,et al.Irinotecancembined with fluorouracil compared with fluorouracil alone asfhst-line treat-ment for metastatic colorectal cancer:a multi-centre randomised tri-al.Lancet,2010,355(9209):1041-1047.
  • 4王鹏,朱珠,李大魁.抗肿瘤药氟脲脱氧核苷的药物动力学与临床应用[J].中国临床药学杂志,2000,9(6):385-388. 被引量:4

二级参考文献19

  • 1[8]Muggia Frank M, Chan Kenneth K, Russell Christy, et al. Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine. Cancer Chemother Pharmacol, 1991, 28: 241
  • 2[9]Ishiwata Kiichi, Tsurumi Yuji, Kameyama Motonobu, et al. Brain tumor accumulation and plasma pharmacokinetic parameters of 2′-deoxy-5-18F-fluorouridine. Annals of Nuclear Medicine, 1993, 7:199
  • 3[10]Foth H, Hellkamp J, Kunellis EM, et al. Pulmonary elimination and metabolism of 5-fluoro-2′-deoxyuridine in isolated perfused rat lung and lung slices. The American Society for Pharmacology and Experimental Therapeutics, 1990, 18:1011
  • 4[11]Israel Valeric K, Jiang Chun, Muggia Franco M, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol, 1995, 37:32
  • 5[12]Rougier Philippe, Laplanche Agnes, Huguier Michel, et al. Hepatic arterial infusion of floxuridne in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncology, 1992, 10:1112
  • 6[13]Van Laar JAM, Durrani FA, Rustum YM. Antitumor activity of the weekly push schedule of 5-fluoro-2′-deoxyuridine±N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res, 1993, 53:1560
  • 7[14]Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metatases from colorectal cancer. J National Cancer Institute, 1996, 88:252
  • 8[15]De Takats PG, Kerr DJ, Poole CJ, et al. Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer, 1994, 69:372
  • 9[16]Marsh John C, Durivage Henry J, Davis Carol, et al. Phase Ⅱ study of pulse 5-fluoro-2′-deoxyuridine and leuco-vorin in advanced colorectal cancer patients previously treated with chemotherapy. J Clin Oncol, 1992, 15:115
  • 10[17]Levin RD, Gordon J. Fluorodeoxyuridine with continuous leucovorin infusion. A phase Ⅱ clinical trial in patients with metastatic colorectal cancer. Cancer, 1993, 72:2895

共引文献3

同被引文献17

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部